Central sleep apnoea syndrome in patients with chronic heart disease: a critical review of the current literature

T Köhnlein, T Welte, L B Tan, M W Elliott

The prevalence, prognosis, clinical presentation, pathophysiology, diagnosis, and treatment of the central sleep apnoea syndrome (CSAS) are reviewed and its relationship with congestive heart failure (CHF) is discussed. Adequately powered trials are needed with survival and health status as end points to establish whether correction of sleep related breathing abnormalities improves the outcome in patients with CHF.

In recent years a number of studies have been published investigating the relationship between chronic congestive heart failure (CHF) and the central sleep apnoea syndrome (CSAS). CSAS has a hypercapnic and a hypocapnic form. The hypercapnic form results from a chronically depressed respiratory drive or ability to breathe, and is associated with hypcapnia during wakefulness and sleep.1 Hypocapnic CSAS, which is discussed in this paper, is much more prevalent. It is not caused by snoring or mechanical obstruction of the upper airway (obstructive sleep apnoea syndrome), but has a completely different cause and pathophysiology (fig 1).2

The typical nocturnal breathing pattern in the majority of patients with periodic CSAS is of periodic breathing, characterised by a regular, crescendo-decrescendo oscillation of tidal volume (fig 2) which is thought to be caused by dysfunction of central respiratory control. As the central drive to breathe slowly fades, ventilation temporarily ceases before resuming again. This results in an oscillation between central hypopnoea (a decrease of ≥50% in the sum of thoracoabdominal movements lasting 10 seconds or more followed by a decrease of ≥4% in peripheral oxygen saturation (SaO2)) or central apnoea (a reduction of >90% in thoracoabdominal movement or complete cessation of ventilatory efforts) and hyperventilation.3 The typical length of one period is 30–60 s, but longer periods have been observed. During a prolonged hypopnoea or apnoea the oxygen saturation decreases, combined with a slow rise in the arterial carbon dioxide tension (PaCO2) and a decline in blood and tissue pH. Central nervous system activity, derived from cortical electroencephalography (EEG), in most cases remains unaffected until late apnoea. However, changes towards lower activity and deeper sleep stages during apnoea have occasionally been found.4 In many cases the resumption of ventilation is associated with EEG arousals, which are markers of central nervous system activation,5 and disturbed sleep which is driven back to a more superficial level.

Cheyne-Stokes respiration (CSR) is commonly used as a synonym for periodic breathing, but some authors distinguish between the two. If the intervals of hyperventilation are separated by hypopnoeas only it is described as periodic breathing, but if both hypopnoeas and apnoeas

Figure 1 Taxonomy of the central sleep apnoea syndrome.
are present it is termed CSR (fig 2). In this review, hypopnoea CSAS and periodic breathing are used as synonyms. It had been suggested that three or more successive periods are necessary for the diagnosis of periodic breathing, but there is no generally accepted definition.

In most patients periodic breathing is present during light sleep stages 1 and 2 and rarely during rapid eye movement (REM) sleep. The amount of periodic breathing varies widely between different patients, but seems to be constant over successive nights in an individual.

**PREVALENCE**

Although found in a number of diseases and in some normal subjects, particularly at high altitude, the highest prevalence of CSAS is found in patients with severe chronic left ventricular insufficiency, in whom it was first described by Cheyne in 1818 and again by Stokes in 1854. Recent reports estimate the prevalence of periodic breathing varies widely between different patients, but seems to be constant over successive nights in an individual.

**CHARACTERISTICS AND PROGNOSIS IN HEART FAILURE**

The presence of periodic breathing during sleep in patients with CHF has significant implications. Patients with CHF and periodic breathing are more limited in their physical performance and develop dyspnoea at lower workloads than patients with disease of similar severity but without periodic breathing. On average, the left ventricular ejection fraction is lower in patients with periodic breathing and the prevalence of cardiac arrhythmia is significantly higher than in patients with the same degree of heart failure but without periodic breathing.

The prognosis of patients is worse if CHF is associated with a sleep apnoea syndrome. Hanly and co-workers conducted a survey of patients in chronic CHF with and without nocturnal CSR matched for age, sex, body mass index, severity and duration of heart disease, and cardiac medication. The cumulative survival and transplant free rate was significantly worse for patients with CSR (100% v 66% after 1 year, 86% v 56% after 2 years, respectively; fig 3). The apnoea-hypopnoea index (see below) has been shown to be an independent predictor of poor prognosis. Andreas and co-workers found an increased likelihood of dying within a few months in patients with CHF and CSR during wakefulness. Complex arrhythmias, including (non-sustained) ventricular tachycardia, are much more prevalent in patients with CSR.

**CLINICAL PRESENTATION**

The typical symptoms of CSAS are daytime hypersomnolence and fatigue. Repetitive arousals cause sleep fragmentation with a reduction in the amount of slow wave and REM sleep which are the most refreshing sleep stages. Artificial sleep fragmentation in volunteers has been shown to result in excessive daytime hypersomnolence, similar to the symptoms of patients suffering from CSAS.
Many patients are likely to fall asleep in quiet or monotonous situations or whenever they are not occupied during the day. Despite apparently sleeping for many hours during the night, patients with CSAS may not feel fully refreshed. These symptoms impair patients' quality of life and may contribute to their sedentary life style. However, the symptoms of CHF such as lethargy, impaired exercise capacity, and paroxysmal nocturnal dyspnoea may overlap with the symptoms of the sleep apnoea syndrome. Fatigue can also be a side effect of cardiac medication—for example, beta blockers—but hypersomnolence and excessive lethargy should alert the clinician to the possibility of CSAS.

PATHOPHYSIOLOGY OF PERIODIC BREATHING

In healthy subjects the tidal volume and frequency of breathing (minute ventilation) is principally controlled by the arterial carbon dioxide tension (PaCO₂), blood pH, and the arterial oxygen tension (PaO₂). These parameters are sensed in the arterial blood by peripheral chemoreceptors located in the carotid bodies and the aortic arch and are thought to react rapidly to short term changes in them. The central chemoreceptors are probably located at the ventral surface of the medulla oblongata, behind the blood brain barrier, which delays responses to changes in arterial blood gas tensions. It has been hypothesised that the central chemoreceptors determine the long term target range of blood gases. Information from these chemoreceptors is transferred to and processed in the respiratory centre in the brain stem, adjacent to centres which control the cardiovascular system. The relationship of the respiratory centre to other brain centres which might also influence the control of breathing—for example, circadian rhythm, sleep-wake rhythm, sleep stage, voluntary influence—is still being investigated. Further inputs into the respiratory centre come from pulmonary J receptors which measure stretch in the airways and the lungs, and from proprioceptors in the respiratory muscles of the diaphragm and the chest wall. Output from the respiratory centre is conducted by efferent nerves to the respiratory muscles—the "ventilatory pump".

The respiratory centre maintains blood gas tensions within a tight range according to the metabolic demands of the body. Periodic breathing reflects uncompensated instability of the feedback control of ventilation. In general, feedback control systems destabilise if their damping capacity or if other mechanisms of keeping the balance are overridden. This can occur if information transfer to the controller is delayed or controller gain is altered.

**Delayed information transfer**

Patients with left ventricular dysfunction and low cardiac output typically have a prolonged circulation time. Pryor speculated about 50 years ago that this might lead to a time delay between changes in blood gas tensions in the lung and their detection in the central nervous system, adversely affecting the control of ventilation. However, several recent studies have not been able to show a predisposition or statistical association between low cardiac output and periodic breathing in patients with CHF.

**Increased controller gain**

Increased controller gain occurs if the sensitivity of chemoreceptors is increased. Various hormones and drugs can alter the human chemoreceptor sensitivity, including the endogenous catecholamines noradrenaline and adrenaline. Levels of both hormones are increased in the blood and urine of patients with heart failure, probably as compensation for cardiac pump failure. Increased circulating concentrations of these catecholamines might increase the responsiveness of the respiratory controller to carbon dioxide, leading to hyperventilation. Latent hyperventilation during wakefulness is a common finding in these patients and a relationship between an abnormally increased ventilatory response to carbon dioxide during the day and periodic breathing during sleep has been observed. Their PaCO₂ is typically in the lower normal range or even below, keeping ventilation closer to the threshold of apnoea. Javaheri showed that patients with CHF and CSAS had a significantly greater sensitivity to carbon dioxide (by a factor of 2.3–3.5) than patients with CHF without CSAS. In a study of 20 men with stable advanced CHF he found a significant positive correlation between sensitivity to carbon dioxide during wakefulness and the number of episodes of apnoea and hypopnoea per hour of sleep. However, this statistical observation does not provide physiological evidence that a low daytime PaCO₂ indicates enhanced chemosensitivity.

Chemoreceptor gain can be diminished pharmacologically by benzodiazepines, dopamine, codeine, morphine, and alcohol, and codeine and morphine have been shown in small clinical studies to reduce the amount of periodic breathing in patients with heart failure.

With apnoea or hypopnoea gas exchange in the lung is reduced, resulting in a rapid fall in oxygen and a rise in carbon dioxide to mixed venous levels. Arousals are frequently observed towards the end of these respiratory events, triggering an increased respiratory responsiveness to carbon dioxide and therefore reducing the damping of respiratory control. This induces an accelerating ventilatory drive producing tidal volumes and frequencies that overshoot what was required to normalise blood gases. The net effect is a reduction in PaCO₂ below the apnoeic threshold, thereby precipitating the apnoeic/hypopnoeic phase and thus perpetuating the cyclic periodic breathing. The arousal related change in the drive to breathe is likely to be very important in sustaining periodic breathing, and provides an explanation for the ventilation overshoot following apnoea and why periodic breathing is not seen in deep sleep.

Episodes of periodic breathing are only transient phenomena in many patients, whereas impaired cardiac function, delayed circulation time, and increased chemoreceptor susceptibility are present chronically. This observation lends further support for the hypothesis that other factors contribute to the control of ventilation. Periodic breathing is usually seen only during wakefulness and light sleep stages, and is markedly attenuated or disappears during REM sleep. It is closely related to a shift in sleep stages, confirming that other brain centres also have a role in the control of ventilation. The respiratory centre also gains information from pulmonary vagal afferents, transmitted by J receptors and C fibres which are activated by tissue stretching. Solin and co-workers demonstrated an inverse relationship between awake pulmonary capillary wedge pressure and awake PaCO₂. If pulmonary oedema activates tissue receptors, or if hyperventilation is induced by impaired oxygen transfer in the congested lung.

Figure 3 Cumulative survival of patients in chronic heart failure (CHF) with or without Cheyne-Stokes respiration (CSR). Reproduced with permission from Hanly and Zuberi-Khokhar.
Paco₂ may fall below the apnoea threshold. A single deep breath is a common finding at the onset of a sequence with periodic breathing and, because during light sleep ventilation is exclusively metabolically controlled, the fall in Paco₂ caused by these events takes it below the apnoea threshold initiating periodic breathing (fig 4). Francis and co-workers recently performed a quantitative general analysis of the dynamic physiology governing cardiorespiratory stability in CHF. Their mathematical model was clinically well validated and revealed the increased chemoreflex gain, long lag to chemoreflex response, low ventilation, low cardiac output, large difference between alveolar and atmospheric carbon dioxide tensions, and small lung volume as critical factors for the development of oscillations in the feedback control of ventilation. However, the model cannot explain why periodic breathing in many patients is a temporary phenomenon. As outlined above, the two key parameters—chemoreflex gain and processing of signals in the brain stem—might be related to the influence of other brain centres.

Haemodynamic factors presumably also play an important role in the pathogenesis of periodic breathing. During sleep the circulatory system is downregulated with a lower heart rate, arterial pressure, and cardiac output. When the patient is recumbent, an increase in preload may paradoxically reduce cardiac output by increasing functional mitral regurgitation as the mitral valve ring is stretched further. Alternatively, the attendant increased filling into the right ventricle and the redistribution and exacerbation of pulmonary oedema when lying supine may lead to increased right ventricular preload and afterload, respectively, thereby enhancing the reversed Bernheim effect which compromises left ventricular filling thus lowering cardiac output. The decreased cardiac output renders the patient susceptible to periodic breathing. Increasing cardiac output through vasodilator or positive inotropic therapy may reduce the incidence of periodic breathing.

**CONSEQUENCES OF PERIODIC BREATHING**

During hypopnoea and apnoea the declining intra-alveolar oxygen content of the lung can cause an increase in right ventricular afterload (Euler-Liljestrand mechanism). The end systolic and end diastolic volumes of the right ventricle increase, producing a gradual shift of the interventricular septum towards the left ventricle (reversed Bernheim effect). This impairs ventricular filling and decreases the end diastolic volume of the left ventricle resulting in a diminished left ventricular output. It can be speculated that this is particularly likely if the myocardium is weakened by cardiomyopathy or ischaemic heart disease.

Arousals may also be associated with direct activation of the sympathetic nervous system. As a result, there is increased noradrenaline spillover in many organs and raised adrenaline and noradrenaline levels in the blood. The amount of catecholamines and their metabolites in overnight urine collections is proportional to the amount of periodic breathing and the number of arousals in patients with CHF and periodic breathing during sleep. Direct measurements of sympathetic activity in peripheral nerve fascicles revealed a close correlation between arousals in the cortical EEG and sympathetic nerve discharge. Further markers of sympathetic activation during arousal are a simultaneous increase in EEG activity, heart rate, and arterial blood pressure. Detailed analysis of heart rate variability around arousal reactions reveals cyclic sympathetic activation and vagal withdrawal. Chronically increased catecholamine concentrations resulting from structural impairment of the heart are therefore exacerbated by periodic breathing. This might precipitate cardiac arrhythmias and downregulate the expression of catecholamine receptors, and could result in a vicious circle with continuously increasing catecholamine levels. The unfavourable effects of endogenous catecholamines in CHF are widely recognised. Recent studies have shown that catecholamines induce a direct toxic effect on cardiac myocytes in vivo and subsequent myocardial fibrosis and an enhancement of cardiac myocyte hypertrophy.

The most critical situation in periodic breathing is during late apnoea when arousal occurs. At this time the heart is supplied with the smallest amount of oxygen and sympathetic activation with rapid release of catecholamines exposes the
heart to further stress. In patients with severe periodic breathing several hundred of these episodes may occur during one night. This has given rise to speculation that these repetitive increases in cardiac stress might contribute to the poorer prognosis of patients with periodic breathing.24

**DIAGNOSIS**

Full polysomnography is regarded as the “gold” standard for diagnosing CSAS. The typical ventilatory pattern of periodic breathing is identified visually according to the guidelines of the American Thoracic Society.1 It can usually be distinguished from the obstructive sleep apnoea syndrome which is characterised by cessation of oronasal air flow with persistence of thoracoabdominal ventilatory efforts. However, in some cases it can be difficult to exclude secondary airway collapse, which might occur in the late phase of a central apnoea. Patients with periodic breathing must be distinguished from those with mixed apnoeas of primarily obstructive aetiology. Obstructive apnoeas are sometimes followed by reflex central apnoeas, superficially mimicking primary central apnoea.22

Several indices describing the severity of the disorder have been established, such as the duration of periodic breathing as a proportion of the total sleep time, the apnoea-hypopnoea index (AHI) which calculates the mean number of events in one hour of sleep, the arousal index, and the oxygen saturation. Up to 15 apnoeic or hypopnoeic episodes per hour of sleep can be considered as normal or mild, 15–30 episodes per hour reflect moderate sleep apnoea, and an AHI of >30 indicates severe sleep apnoea.29

**Screening systems** which measure a limited number of sleep parameters and interpret the sleep study automatically without allowing direct visualisation of the raw data are not sufficient diagnostic tools for CSAS.29

**TREATMENT**

Before considering specific treatment for periodic breathing, medical treatment of the underlying heart disease must be optimised.30 31 Improvement in cardiac output has been shown to reduce periodic breathing.52 53 Other confounding conditions which might influence breathing during sleep (such as neurological disorders or drugs) must be ruled out.

Treatment for periodic breathing includes nocturnal non-invasive ventilation and oxygen application via nasal cannulae (table 1).30 31 Drugs such as theophylline, morphine derivatives, and supplementation of inhaled air with 3% carbon dioxide have been applied under experimental conditions in small studies.33–36 The prescription of sedatives for patients with any form of sleep disordered breathing should be

---

**Table 1** Key references for pathophysiology and treatment of central sleep apnoea syndrome (CSAS)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Summary</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naughton et al3</td>
<td>Controlled study with a CPAP treatment period of 1 month. Pressure: 10.2 (0.5) cm H2O. In a subgroup of 12 patients CPAP significantly reduced the frequency of apnoeas and hypopnoeas, increased the oxygen saturation and PCO2, and normalised minute volume during sleep</td>
<td>Comprehensive study suggesting CPAP as an additional treatment option for chronic heart failure patients</td>
</tr>
<tr>
<td>Naughton et al4</td>
<td>Randomised controlled study with a CPAP treatment period of 3 months. Subjects: 12 patients in the control group (no CPAP) and 12 patients in the treatment group (10.1 (0.5) cm H2O). Significant improvements were found for the following parameters: apnoeas and hypopnoeas during sleep, arousals during sleep, left ventricular ejection fraction during wakefulness, symptoms of fatigue, and disease mastery</td>
<td>Extension of the study above, reaching good quality standards for clinical trials, and confirming CPAP as a beneficial treatment option for the CSAS</td>
</tr>
<tr>
<td>Javaheri25</td>
<td>A one night CPAP treatment was performed in 29 patients with CHF. 16 responded to treatment, determined by a significant reduction in apnoeas, hypopnoeas, arousals, percentage of total sleep time below a saturation of 90%, and lowest saturation. 13 did not respond to CPAP. Responders had a highly decreased frequency of premature ventilatory contractions and couplets</td>
<td>Javaheri identified responders and a high proportion of non-responders in his study population. The results in responders are similar to the results in the studies above</td>
</tr>
<tr>
<td>Willson et al46</td>
<td>Eleven patients were started on a 3 month home trial with nocturnal controlled nasal intermittent positive pressure ventilation (nIPPV). Ventilatory parameters were set in such a way that the PCO2 was maintained at or slightly below the patient’s awake level. nIPPV abolished periodic breathing in all patients with a significant improvement in the sleep architecture, frequency of apnoeas and hypopnoeas, arousals, and a significant increase in left ventricular ejection fraction. Long-term domiciliary usage of the device was poor; only 6 patients completed the 3 month trial</td>
<td>Volume controlled ventilation and slight hyperventilation does not seem to be an adequate treatment option for the majority of patients</td>
</tr>
<tr>
<td>Hanly et al47</td>
<td>Nine patients were included in a randomised placebo controlled crossover study administering 2–3 l/min oxygen or compressed air for one night. Oxygen reduced Cheyne-Stokes respiration by 50%, mainly in stage 1 sleep, with no significant changes in the other sleep stages. The sleep architecture was improved, the same was found for apnoeas, hypopnoeas, and arousals</td>
<td>Low flow oxygen is effective in reducing apnoeas and hypopnoeas in patients with CHF, but its therapeutic benefit is much lower than CPAP</td>
</tr>
<tr>
<td>Andreas et al48</td>
<td>Similar study design and results to Hanly’s study, but exercise performance, measured as peak oxygen uptake, improved significantly in the 22 participants after 1 week of treatment with 4 l/min oxygen during sleep. Cognitive function improved as well, but no change was found in daytime symptoms</td>
<td>This is the only study evaluating exercise capacity, an important parameter for patients after treatment of central sleep apnoea</td>
</tr>
<tr>
<td>Franklin et al49</td>
<td>Prospective intervention study of 20 patients, 16 with chronic heart failure. During one treatment night oxygen doses had been titrated individually, and in 17 of 20 patients the frequency, but not the duration, of central apnoeas was reduced significantly. The arousals were also reduced, but the effect on total sleep time and daytime sleepiness was very variable</td>
<td>The interindividual differences of the effect of oxygen was very variable in this study, despite an individual titration of oxygen flow. Oxygen eliminated some central apnoeas, whereas the majority of events remained unchanged</td>
</tr>
<tr>
<td>Xie et al50</td>
<td>Six patients with idiopathic CSAS had been treated with 3% CO2 in their inhalation gas or with a full face mask, enlarging ventilatory dead space. PCO2 increased between 1.3 and 2.4 mm Hg and apnoeas and hypopnoeas were virtually eliminated</td>
<td>Hyperventilation below the threshold of apnoea plays a key role in central apnoeas. Increasing PCO2 in patients with CSAS seems to make these events less likely</td>
</tr>
</tbody>
</table>

CPAP = continuous positive airway pressure; PCO2 = carbon dioxide tension; CSAS = central sleep apnoea syndrome; CHF = congestive heart failure.
discouraged. In these patients slow wave and REM sleep, which are the refreshing sleep stages, are already reduced due to frequent arousals. The use of benzodiazepines in particular can further reduce slow wave and REM sleep, resulting in worsening of daytime symptoms. By blunting arousal responses they may worsen nocturnal gas exchange.87

In the absence of major prospective randomised controlled trial data, the indications for treatment remain to be defined, but it should be considered when there are frequent and severe oxygen desaturations during sleep resulting from recurrent hypopneas or apnoeas, a high prevalence of arousals and sympathetic nervous system activation, and severe disruption of sleep architecture (reduced amount of slow wave or REM sleep) with subsequent daytime hypersomnolence.91

Oxygen

The application of oxygen at a rate of 4 l/min via nasal cannulae has been shown to influence nocturnal periodic breathing. Some investigators have reported an almost complete abolition of periodic breathing and an improved mean overnight oxygen saturation,92 whereas others observed only a partial (approximately 50%) reduction in the number of hypopneas and apnoeas.6769 Andreas et al67 found a significant increase in exercise tolerance (peak oxygen consumption) in a cohort of 22 heart failure patients with periodic breathing during sleep after 1 week of nocturnal oxygen therapy. The same study revealed a significant correlation between the increase in peak oxygen consumption during ergospirometry and a decrease in CSR, in arousals, and in the amount of time spent in bed with an oxygen saturation <90%. Staniforth and colleagues68 conducted a randomised, double blind, crossover study comparing oxygen with room air in 11 patients with stable CHF. Four weeks of nocturnal oxygen treatment reduced the amount of apnoeas and periodic breathing during sleep, as well as the nocturnal urinary noradrenaline excretion. No significant changes in sleep quality, patient symptoms, or cognitive function were identified. It has been postulated that the limited effect of high oxygen concentrations is due to enhanced cellular metabolism in the peripheral chemoreceptors and a subsequent alteration of their setting.90

Continuous positive airway pressure (CPAP)

CPAP or non-invasive ventilation has been used for the treatment of patients with periodic breathing during sleep. Although the mechanism of action of CPAP is not fully understood in patients with CSAS, it has been shown to be an effective method of treatment.106 107 It can be difficult to introduce CPAP in some patients,101 but a relatively low pressure level of 3.7 mm Hg has been shown to be effective in adults with a normal body mass index.108 It stabilises the patient’s ventilation and reduces the amount of periodic breathing, apnoeas, hypopnoeas, arousals, and the number of oxygen desaturations during sleep. The mean oxygen saturation increases and the transcutaneous carbon dioxide pressure increases back into the normal range.107

Studies of activation of the sympathetic nervous system during treatment with CPAP have shown a significant reduction in the excretion of noradrenaline, but not of adrenaline, in several studies.66 CPAP also has direct haemodynamic effects, increasing the intrathoracic pressure and thereby reducing cardiac afterload and preload by reducing venous return to the right atrium. This results in lower diastolic filling pressures and more effective pump function.108 109 CPAP recruits atelectatic lung areas, improving oxygen transfer in the lungs, and the higher intrapulmonary oxygen content might prevent recurrent rises of right ventricular afterload and subsequent pulmonary hypertension.110 However, a recently published randomised study investigating patients with CHF with and without periodic breathing revealed an improvement in left ventricular ejection fraction and in mortality in patients with periodic breathing only, suggesting that any beneficial effect from CPAP is a consequence of an improvement in periodic breathing.111

In summary, current therapeutic approaches have focused on correction of the pathological breathing pattern. The effect of oxygen seems to be less successful than CPAP or non-invasive ventilation. There are no conclusive studies of the long term outcome of any treatment of CSAS. Many investigators prefer CPAP for treatment of periodic breathing because of the possible benefit of its direct mechanical effects on the failing heart.107 However, the development of new treatment strategies must be encouraged to find new approaches to the instability of the control of breathing in some patients with congestive cardiac failure.107 These may include different forms of non-invasive ventilation108 or drugs influencing the central control of carbon dioxide.109

CONCLUSIONS

CSAS with periodic breathing occurs frequently but is often unrecognised in patients with advanced CHF. In many patients, daytime fatigue and impaired physical performance is not just a symptom of the heart disease or side effect of treatment, but an indicator of sleep disordered breathing. The prognosis of patients with CHF seems to be significantly worse if CSAS is present. The causal relationship between CHF and CSAS is not fully understood, but delayed circulation time, increased chemoreceptor sensitivity to carbon dioxide, input into the respiratory centre from other brain centres and from peripheral receptors might have pathophysiological importance. Treatment options include CPAP and supplemental oxygen. CPAP is the most widespread treatment but, because of relatively poor patient acceptance in some studies, more sophisticated ventilatory support strategies need to be developed. Adequately powered prospective randomised controlled trials with survival and health status as end points are needed to establish whether the correction of sleep related abnormalities of breathing in patients with heart failure really does improve outcome.

ACKNOWLEDGEMENTS

TK was supported on a Long Term Research Fellowship funded by the European Respiratory Society. The authors thank Dr S B Pearson for helpful comments on the manuscript.

REFERENCES


www.thoraxjnl.com
Central sleep apnoea syndrome in patients with chronic heart disease

10 Cheyne J. A case of apoplexy in which the flabby part of the heart is turned to fist. Dublin Hospital Report 1818; 2:216–23.


